4.5 Article

Evidence that alpha-calcitonin gene-related peptide is a neurohormone that controls systemic lipid availability and utilization

Journal

ENDOCRINOLOGY
Volume 149, Issue 1, Pages 154-160

Publisher

ENDOCRINE SOC
DOI: 10.1210/en.2007-0583

Keywords

-

Ask authors/readers for more resources

alpha-Calcitonin gene-related peptide (alpha CGRP) is released mainly from sensory and motor nerves in response to physiological stimuli. Despite well-documented pharmacological effects, its primary physiological role has thus far remained obscure. Increased lipid content, particularly in skeletal muscle and liver, is strongly implicated in the pathogenesis of insulin resistance, but the physiological regulation of organ lipid is imperfectly understood. Here we report our systematic investigations of the effects of alpha CGRP on in vitro and in vivo indices of lipid metabolism. In rodents, levels of alpha CGRP similar to those in the blood markedly stimulated fatty acid beta-oxidation and evoked concomitant mobilization of muscle lipid via receptor-mediated activation of muscle lipolysis. alpha CGRP exerted potent in vivo effects on lipid metabolism in muscle, liver, and the blood via receptor-mediated pathways. Studies with receptor antagonists were consistent with tonic regulation of lipid metabolism by an endogenous CGRP agonist. These data reveal that alpha CGRP is a newly recognized regulator of lipid availability and utilization in key tissues and that it may elevate the availability of intramyocellular free fatty acids to meet muscle energy requirements generated by contraction by evoking their release from endogenous triglyceride.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Pharmacology & Pharmacy

Beyond CGRP: The calcitonin peptide family as targets for migraine and pain

Tayla A. Rees, Erica R. Hendrikse, Debbie L. Hay, Christopher S. Walker

Summary: In addition to CGRP, calcitonin family peptides may be therapeutically useful in treating migraines and other pain disorders. Their localization in peripheral pain pathways could play a role in migraines and pain.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Review Pharmacology & Pharmacy

CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists?

Michael L. Garelja, Christopher S. Walker, Debbie L. Hay

Summary: The development of drugs targeting the CGRP system has been a major breakthrough in migraine management. These drugs can be classified into antibodies and receptor antagonists, with receptor antagonists further divided into small molecule antagonists and antibody antagonists. While antagonists are most potent at the CGRP receptor, they may also show antagonism at the AMY(1) receptor, indicating the need for further research.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Pharmacological characterisation of mouse calcitonin and calcitonin receptor-like receptors reveals differences compared with human receptors

Michael L. Garelja, Rebekah L. Bower, Margaret A. Brimble, Shanan Chand, Paul W. R. Harris, Muhammad Aqfan Jamaluddin, Jakeb Petersen, Andrew Siow, Christopher S. Walker, Debbie L. Hay

Summary: The pharmacology of the mouse CLR/CTR and RAMPs receptors differs from that of humans, with mouse receptors showing reduced discrimination between ligands, posing challenges for interpreting data in preclinical models and translating findings from mice to humans. New ligands are needed to differentiate between these complexes.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Characterisation of agonist signalling profiles and agonist-dependent antagonism at PACAP-responsive receptors: Implications for drug discovery

Zoe Tasma, Andrew Siow, Paul W. R. Harris, Margaret A. Brimble, Debbie L. Hay, Christopher S. Walker

Summary: The PACAP-responsive receptors exhibit varied pharmacological profiles but activate signaling in a similar manner. The PAC(1s) receptor can act as a dual receptor for VIP and PACAP. The effectiveness of blocking a signaling pathway can be influenced by the endogenous PACAP family agonist present, with PACAP-38 showing less antagonism compared to PACAP-27 and VIP.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Article Clinical Neurology

Calcitonin receptor antibody validation and expression in the rodent brain

Erica R. Hendrikse, Tayla A. Rees, Zoe Tasma, Christelle Le Foll, Thomas A. Lutz, Andrew Siow, Peter J. Wookey, Christopher S. Walker, Debbie L. Hay

Summary: This study examined the expression of the calcitonin receptor protein subunit in the rodent brain and found that it was present in several brain regions relevant to migraine. The findings suggest a potential link between the calcitonin gene-related peptide and migraine, but further research is needed to understand the functional consequences of calcitonin receptor expression.

CEPHALALGIA (2022)

Article Multidisciplinary Sciences

A structural basis for amylin receptor phenotype

Jianjun Cao, Matthew J. Belousoff, Yi-Lynn Liang, Rachel M. Johnson, Tracy M. Josephs, Madeleine M. Fletcher, Arthur Christopoulos, Debbie L. Hay, Radostin Danev, Denise Wootten, Patrick M. Sexton

Summary: The structure and dynamics of AMYRs with amylin and CT were studied, revealing the role of RAMP and the presence of a bypass motif. The binding mechanism of CT-based peptides to AMYRs is distinct from that of amylin-based peptides. This finding has implications for the development of AMYR therapeutics.

SCIENCE (2022)

Review Clinical Neurology

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond

Michael L. Garelja, Debbie L. Hay

Summary: A comprehensive understanding of the pharmacology and relationship to migraine of the calcitonin peptide family of receptors is important in the development of new anti-migraine drugs and the interpretation of the mechanism of action of current drugs.

HEADACHE (2022)

Article Biochemistry & Molecular Biology

PAC1, VPAC1, and VPAC2 Receptor Expression in Rat and Human Trigeminal Ganglia: Characterization of PACAP-Responsive Receptor Antibodies

Zoe Tasma, Andrew Siow, Paul W. R. Harris, Margaret A. Brimble, Simon J. O'Carroll, Debbie L. Hay, Christopher S. Walker

Summary: This study validated commercially available antibodies and used them to detect PACAP-responsive receptors in the trigeminal ganglia. Antibodies that could differentiate between receptor splice variants were identified, and expression of multiple receptors in neuronal and glial-like cells was observed. These findings suggest that these receptors are potential targets for migraine treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Biochemistry & Molecular Biology

Characterization of Antibodies against Receptor Activity-Modifying Protein 1 (RAMP1): A Cautionary Tale

Erica R. R. Hendrikse, Tayla A. A. Rees, Zoe Tasma, Michael L. L. Garelja, Andrew Siow, Paul W. R. Harris, John B. B. Pawlak, Kathleen M. M. Caron, Elizabeth S. S. Blakeney, Andrew F. F. Russo, Levi P. P. Sowers, Thomas A. A. Lutz, Christelle Le Foll, Christopher S. S. Walker, Debbie L. L. Hay

Summary: This study evaluated antibodies for the detection of RAMP1 protein and found that two antibodies could detect a RAMP1-like band in rodent brain tissue, but with cross-reactivity to other proteins. The anatomical localization of RAMP1 in the brain could not be determined, highlighting the need for comprehensive validation of RAMP1 antibodies. This research has broader implications for GPCR/ligand pairings beyond the field of CGRP.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Editorial Material Biochemistry & Molecular Biology

Comment on Yoo et al. Amylin Protein Expression in the Rat Brain and Neuro-2a Cells. Int. J. Mol. Sci. 2022, 23, 4348

Tayla A. A. Rees, Debbie L. L. Hay, Christopher S. S. Walker

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Pharmacology & Pharmacy

Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins

Ilana B. Kotliar, Emily Lorenzen, Jochen M. Schwenk, Debbie L. Hay, Thomas P. Sakmar

Summary: G protein-coupled receptors (GPCRs) interact with a variety of membrane proteins, but the extent and mechanisms of these interactions are not well understood. RAMPs, a class of GPCR-interacting proteins, have been extensively studied. Recent research suggests that GPCR-RAMP interactions may be more widespread than previously thought. This review summarizes the latest techniques for discovering GPCR-RAMP interactions and their functional consequences, and discusses future research prospects.

PHARMACOLOGICAL REVIEWS (2023)

Review Physiology

CGRP PHYSIOLOGY, PHARMACOLOGY, AND THERAPEUTIC TARGETS: MIGRAINE AND BEYOND

Andrew F. Russo, Debbie L. Hay

Summary: Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse physiological functions. It acts through various receptors and is associated with disease states such as migraine. Therapeutics targeting the CGRP axis have shown success in bench-to-bedside translation. This review provides a comprehensive overview of CGRP's regulation, expression, physiological actions, and potential therapeutic targeting in various systems and diseases.

PHYSIOLOGICAL REVIEWS (2023)

Article Medicine, General & Internal

Elevated hippocampal copper in cases of type 2 diabetes

Sasha A. Philbert, Sarah J. Schoenberger, Jingshu Xu, Stephanie J. Church, Richard D. Unwin, Garth J. S. Cooper

Summary: The study found that hippocampal copper levels were significantly elevated in patients with T2D, similar to untreated cases of Wilson's disease (WD), while hippocampal copper levels were markedly deficient in patients with sAD. These results suggest that hippocampal copper may play a role in the neurodegeneration and cognitive impairment in T2D, and therapeutic approaches targeting copper reduction, similar to those used in WD, may be applicable to patients with T2D.

EBIOMEDICINE (2022)

Article Pharmacology & Pharmacy

Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors

Michael L. Garelja, Tyla I. Alexander, Amy Bennie, Mhairi Nimick, Jakeb Petersen, Christopher S. Walker, Debbie L. Hay

Summary: This study demonstrates that erenumab can antagonize both CGRP and AMY(1) receptors, providing insights into the clinical profile of erenumab.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Medicine, General & Internal

Widespread selenium deficiency in the brain of cases with Huntington's disease presents a new potential therapeutic target

Melissa Schole, Stefano Patassini, Jingshu Xu, Garth J. S. Cooper

Summary: This study observed alterations in metallomic profiles in the Huntington's disease (HD) brain, which may contribute to various pathogenic mechanisms. Selenium supplementation could offer a potential therapeutic pathway for HD treatment, as selenium deficiency is widespread in regions with differing levels of neurodegeneration.

EBIOMEDICINE (2023)

No Data Available